Navigation Links
OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Date:9/3/2009

BOTHELL, WA and VANCOUVER, Sept. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company will webcast presentations at the following investor conferences:

    -   Rodman & Renshaw 11th Annual Healthcare Conference on Thursday,
        September 10, 2009 at 12:30 p.m. Eastern Time in the Fahnestock Salon
        at the New York Palace Hotel in New York City.

    -   Thomas Weisel Partners Healthcare Conference on Friday, September 11,
        2009 at 10:20 a.m. Eastern Time in the Stuart Room at the Four
        Seasons Hotel in Boston.

    -   BioCentury NewsMakers in the Biotech Industry Conference on
        Wednesday, September 16, 2009 at 2:30 p.m. Eastern Time in room
        304/305 at the Millennium Broadway Hotel & Conference Center in New
        York City.

Access to a live webcast of each of the presentations will be available on the Events Presentation section of the Investor Relations page on the company Web site at www.oncogenex.com. A replay of each webcast will be available for 30 days following the event.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, ... Actuator with a flexure design that ensures high alignment accuracy by preventing unwanted ... is ideally suited where extreme precision is required, such as in medical equipment, ...
(Date:11/30/2016)... New York , November 30, 2016 ... consolidated as a few players hold a dominant share ... Group, Charles River Laboratories International, Inc., and Merck KGaA, ... market in 2015. Transparency Market Research observes that these ... are focused on development products that are do not ...
(Date:11/30/2016)... 2016 Biotest Pharmaceuticals Corporation (BPC), a leading ... the addition of its newest plasma collection center located ... . The 15,200 square foot state-of-the-art facility officially opened ... brings the total number of BPC,s plasma collection centers ... BPC,s Chief Executive Officer said "We are pleased to ...
Breaking Biology Technology:
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):